Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed glioblastoma multiforme treated with temozolomide (200mg/m2) as monotherapy and patients with recurrent or progressive malignant glioma treated with temozolomide as monotherapy (200mg/m2).~* Male and female patients at least 18 of age.~* Non-pregnant, non-breast feeding female.~* Body mass index (weight/height²) in the range of 18.5 to 30 kg/m².~* Having given a written informed consent~Exclusion Criteria:~* Co-administration of sodium valproate~* Patients with (naso)gastric tubes~* Patients receiving 150 mg/m² and not eligible to the 200 mg/m² dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ped-TMZ (Type: EXPERIMENTAL): Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition.
- Temodal capsule (Type: ACTIVE_COMPARATOR): Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. The administration will take place around 8:00 a.m. followed with 240 mL of tap water, in sitting position and under fasting condition

Based on this trial design, predict the completion outcome and termination type (if applicable).